DRAGON PHARMACEUTICALS mit FDA approval - 500 Beiträge pro Seite
eröffnet am 08.02.07 09:38:15 von
neuester Beitrag 15.05.07 17:17:28 von
neuester Beitrag 15.05.07 17:17:28 von
Beiträge: 18
ID: 1.110.580
ID: 1.110.580
Aufrufe heute: 0
Gesamt: 1.119
Gesamt: 1.119
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 17 Minuten | 9707 | |
| vor 32 Minuten | 6309 | |
| vor 17 Minuten | 3192 | |
| vor 18 Minuten | 3135 | |
| vor 10 Minuten | 3116 | |
| vor 17 Minuten | 2897 | |
| vor 43 Minuten | 2375 | |
| vor 31 Minuten | 2343 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.894,61 | -1,07 | 240 | |||
| 2. | 3. | 163,00 | +0,54 | 90 | |||
| 3. | 4. | 0,1905 | -1,80 | 86 | |||
| 4. | 2. | 9,2550 | -4,04 | 86 | |||
| 5. | 6. | 0,0262 | +24,17 | 60 | |||
| 6. | 14. | 6,9820 | +3,62 | 55 | |||
| 7. | 34. | 0,6450 | -53,93 | 53 | |||
| 8. | 13. | 434,25 | -12,01 | 47 |
Feedback
Hier die News von heute Nacht:
DRAGON PHARMACEUTICALS
FDA Approves alli(TM) (orlistat 60 mg capsules) Over-The-Counter
2/7/2007
An Innovative and Honest Approach to Weight Loss
Combines a Safe and Effective Product With An Innovative Personalized Support Program
PITTSBURGH, Feb 07, 2007 /PRNewswire via COMTEX News Network/ --
PITTSBURGH, Feb. 7 /PRNewswire-FirstCall/-- GlaxoSmithKline [NYSE:GSK] Consumer Healthcare announces today that the U.S. Food and Drug Administration (FDA) approved the weight-loss product orlistat 60 mg capsules for over-the-counter (OTC) use in the United States. GSK Consumer Healthcare will market OTC orlistat under the brand name alli(TM) (pronounced AL-eye). Approved for use by overweight adults in conjunction with a reduced-calorie, low-fat diet, alli helps people lose 50 percent more weight than with diet alone. alli is the only FDA-approved weight-loss product available to consumers without a prescription, and it is the first clinically-proven over- the-counter product to be combined with a comprehensive support program. alli is expected to be available in stores nationwide by summer 2007. This approval marks the start of an educational program that includes a series of resources online at myalli.com.
GSK Consumer Healthcare selected alli as the brand name because it conveys the concept of partnership with consumers in their weight-loss efforts. Consumers spend billions of dollars each year on fad diets, unproven miracle pills, and potentially unsafe weight-loss supplements that may not work. alli is the clinically proven option to these hyped, quick-fix products that mislead overweight adults away from weight-loss strategies that are backed by medical science. With alli, consumers have access to an individually tailored online action plan that provides support and the necessary tools to help them lose 50 percent more weight than with diet alone.
Caroline Apovian, M.D., Director of the Center for Nutrition and Weight Management at Boston Medical Center welcomed the FDA decision. "I applaud the alli program for stressing the importance of a reduced-calorie, low-fat diet in conjunction with a weight-loss medicine proven to be safe and effective. This lines up with research that shows even modest, gradual weight loss provides significant health benefits." Apovian adds, "More and more people each year -- now two-thirds of all American adults -- are overweight or obese and still gaining weight.
Desperate to lose this excess weight, people resort to all types of extreme methods that promise everything and deliver no real results. Extremely restrictive diets are unrealistic to maintain, even for a couple of weeks. Dieters end up gaining more weight than they initially lost. It's time consumers readjust their thinking to realize positive results."
Why alli is Different
Unlike other products on store shelves, alli is a proven medicine with a comprehensive support program. To help consumers get off to a successful start, the alli package will include Welcome and Companion Guides, a Guide to Healthy Eating, a Daily Journal, a Calorie and Fat Counter, Quick Fact Cards, and free access to an individualized online action plan at myalli.com.
"With alli, we're excited to offer a revolutionary approach to weight loss," says Steven L. Burton, Vice President, Weight Control, GlaxoSmithKline Consumer Healthcare. "alli is more than a pill -- it's a comprehensive program that works in conjunction with a sensible diet to increase weight loss. Because weight loss doesn't happen overnight, we're starting to educate consumers now about the importance of realistic expectations, gradual weight loss and lifestyle changes. That's the way to see results, and with alli, we know they can do it."
Starting today, GSK Consumer Healthcare will gear up production to have the product ready for shipment and in stores by the summer. The company is using this period to build awareness and understanding about the product and its intended user -- with the message -- alli is not for everyone. It's for the committed consumer who can follow a reduced-calorie, low-fat diet. For this consumer, alli will provide a unique, proven approach to weight loss, offering straight talk, educational tools and an online support program -- myalli.com.
How to Use alli
alli, the only FDA-approved weight-loss product soon to be available without a prescription, is indicated for weight loss in overweight adults 18 years and older when used along with a reduced-calorie, low-fat diet. The recommended dose of alli is one 60 mg capsule three times a day with meals containing fat.
Taken at meal-time, alli works by blocking about 25 percent of the fat in the food a person eats. Because of the way it works, alli must be used in conjunction with a reduced-calorie, low-fat diet containing about 15 grams of fat per meal. The guides and information supplied in the alli package help the consumer to control the amount of fat in their meals, and to follow an appealing, reduced-calorie, low-fat diet. Consuming a meal with too much fat, while taking alli, can result in bowel changes such as having an urgent need to use the bathroom. These changes, called treatment effects, generally occur in the first weeks of treatment, are not harmful, and can be managed by following the recommended diet with about 15 grams of fat per meal. Users should take a multivitamin once a day, at bedtime, because alli can reduce the absorption of some vitamins.
Safety and Efficacy
alli (60 mg orlistat capsules) is safe and effective when used as directed. As the most extensively studied weight-loss medication on the market, the safety and efficacy of orlistat is very well established. A higher dose of orlistat has been marketed as the prescription drug Xenical(R) (orlistat 120 mg capsules) in the U.S. since 1999 and is supported by nine years of worldwide use in 145 other countries. Orlistat experience in more than 25 million patient treatments and more than 100 clinical studies with more than 30,000 patients is unprecedented. One of these studies with Xenical is the four-year landmark XENDOS trial conducted by Roche, its inventor and manufacturer. This study is the longest study ever conducted for a weight-loss medicine.
Xenical (orlistat 120 mg capsules) will remain available by prescription for those who should be treated under the care of a physician. Xenical will continue to be manufactured and sold by Roche.
For more information on alli, go to myalli.com.
About Overweight and Obesity
Currently, approximately 65 percent of U.S. adults are overweight or obese, according to the National Institutes of Health. Research suggests that overweight individuals appear to be on the pathway to obesity.(i, ii) Overweight and obesity are associated with an increased risk of developing health problems such as hypertension, type 2 diabetes and heart disease.(iii) Factors that can contribute to overweight include an abundance of high-calorie foods, low levels of physical activity, behavior, environment, and genetics.(iv) Multiple studies have shown that a modest reduction in weight improves health outcomes significantly in overweight or obese patients.(v, vi)
About GlaxoSmithKline Consumer Healthcare
GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many medicine cabinet staples, including Abreva(R), Aquafresh(R), Sensodyne(R), Tums(R) and Breathe Right(R).
About GlaxoSmithKline
GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: http://www.gsk.com.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report 2004.
(i) Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends
in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
(ii) McTigue KM, Garrett JM, Popkin BM. The natural history of the
development of obesity in a cohort of young US adults between 1981-
1998. Ann Intern Med 2002;136:857-864.
(iii) Centers for Disease Control and Prevention: "Overweight and
Obesity." http://www.cdc.gov/nccdphp/dnpa/obesity/. Accessed
12/22/05.
(iv) Centers for Disease Control and Prevention. "Overweight and Obesity:
Contributing Factors."
http://www.cdc.gov/nccdphp/dnpa/obesity/contributing_factors…
Accessed 12/22/05.
(v) Hauptman J, Lucas C, Baldrin MN, Collins H, Segal K. "Orlistat in
the long-term treatment of obesity in primary care settings."
Archives of Family Medicine 9:160-167.
(vi) NIH, NHLBI. Clinical guidelines on the identification, evaluation,
and treatment of overweight and obesity in adults. HHS, PHS; 1998.
p. 29-41.
SOURCE GlaxoSmithKline Consumer Healthcare
GSK Inquiries, US Media, Brian Jones, +1-215-751-3415, Brian.L.Jones@gsk.com, or
Malesia Dunn, +1-412-200-3544, malesia.a.dunn@gsk.com, or Patricia Seif,
+1-215-751-7709, patricia.r.seif@gsk.com, or US Analyst\Investors, Frank Murdolo,
+1-215-751-7002, or Tom Curry, +1-215-751-5419, or UK Media Inquiries, Philip
Thomson, +020-8047-5502, or Gwenan White, +020-8047-5502, or Alice Hunt,
+020-8047-5502, or European Analyst\Investors Inquiries, Anita Kidgell,
+020-8047-5542, or Sally Ferguson, +020-8047-5543, or David Mawdsley, +020-8047-5564
http://www.prnewswire.com
Copyright (C) 2007 PR Newswire. All rights reserved
DRAGON PHARMACEUTICALS
FDA Approves alli(TM) (orlistat 60 mg capsules) Over-The-Counter
2/7/2007
An Innovative and Honest Approach to Weight Loss
Combines a Safe and Effective Product With An Innovative Personalized Support Program
PITTSBURGH, Feb 07, 2007 /PRNewswire via COMTEX News Network/ --
PITTSBURGH, Feb. 7 /PRNewswire-FirstCall/-- GlaxoSmithKline [NYSE:GSK] Consumer Healthcare announces today that the U.S. Food and Drug Administration (FDA) approved the weight-loss product orlistat 60 mg capsules for over-the-counter (OTC) use in the United States. GSK Consumer Healthcare will market OTC orlistat under the brand name alli(TM) (pronounced AL-eye). Approved for use by overweight adults in conjunction with a reduced-calorie, low-fat diet, alli helps people lose 50 percent more weight than with diet alone. alli is the only FDA-approved weight-loss product available to consumers without a prescription, and it is the first clinically-proven over- the-counter product to be combined with a comprehensive support program. alli is expected to be available in stores nationwide by summer 2007. This approval marks the start of an educational program that includes a series of resources online at myalli.com.
GSK Consumer Healthcare selected alli as the brand name because it conveys the concept of partnership with consumers in their weight-loss efforts. Consumers spend billions of dollars each year on fad diets, unproven miracle pills, and potentially unsafe weight-loss supplements that may not work. alli is the clinically proven option to these hyped, quick-fix products that mislead overweight adults away from weight-loss strategies that are backed by medical science. With alli, consumers have access to an individually tailored online action plan that provides support and the necessary tools to help them lose 50 percent more weight than with diet alone.
Caroline Apovian, M.D., Director of the Center for Nutrition and Weight Management at Boston Medical Center welcomed the FDA decision. "I applaud the alli program for stressing the importance of a reduced-calorie, low-fat diet in conjunction with a weight-loss medicine proven to be safe and effective. This lines up with research that shows even modest, gradual weight loss provides significant health benefits." Apovian adds, "More and more people each year -- now two-thirds of all American adults -- are overweight or obese and still gaining weight.
Desperate to lose this excess weight, people resort to all types of extreme methods that promise everything and deliver no real results. Extremely restrictive diets are unrealistic to maintain, even for a couple of weeks. Dieters end up gaining more weight than they initially lost. It's time consumers readjust their thinking to realize positive results."
Why alli is Different
Unlike other products on store shelves, alli is a proven medicine with a comprehensive support program. To help consumers get off to a successful start, the alli package will include Welcome and Companion Guides, a Guide to Healthy Eating, a Daily Journal, a Calorie and Fat Counter, Quick Fact Cards, and free access to an individualized online action plan at myalli.com.
"With alli, we're excited to offer a revolutionary approach to weight loss," says Steven L. Burton, Vice President, Weight Control, GlaxoSmithKline Consumer Healthcare. "alli is more than a pill -- it's a comprehensive program that works in conjunction with a sensible diet to increase weight loss. Because weight loss doesn't happen overnight, we're starting to educate consumers now about the importance of realistic expectations, gradual weight loss and lifestyle changes. That's the way to see results, and with alli, we know they can do it."
Starting today, GSK Consumer Healthcare will gear up production to have the product ready for shipment and in stores by the summer. The company is using this period to build awareness and understanding about the product and its intended user -- with the message -- alli is not for everyone. It's for the committed consumer who can follow a reduced-calorie, low-fat diet. For this consumer, alli will provide a unique, proven approach to weight loss, offering straight talk, educational tools and an online support program -- myalli.com.
How to Use alli
alli, the only FDA-approved weight-loss product soon to be available without a prescription, is indicated for weight loss in overweight adults 18 years and older when used along with a reduced-calorie, low-fat diet. The recommended dose of alli is one 60 mg capsule three times a day with meals containing fat.
Taken at meal-time, alli works by blocking about 25 percent of the fat in the food a person eats. Because of the way it works, alli must be used in conjunction with a reduced-calorie, low-fat diet containing about 15 grams of fat per meal. The guides and information supplied in the alli package help the consumer to control the amount of fat in their meals, and to follow an appealing, reduced-calorie, low-fat diet. Consuming a meal with too much fat, while taking alli, can result in bowel changes such as having an urgent need to use the bathroom. These changes, called treatment effects, generally occur in the first weeks of treatment, are not harmful, and can be managed by following the recommended diet with about 15 grams of fat per meal. Users should take a multivitamin once a day, at bedtime, because alli can reduce the absorption of some vitamins.
Safety and Efficacy
alli (60 mg orlistat capsules) is safe and effective when used as directed. As the most extensively studied weight-loss medication on the market, the safety and efficacy of orlistat is very well established. A higher dose of orlistat has been marketed as the prescription drug Xenical(R) (orlistat 120 mg capsules) in the U.S. since 1999 and is supported by nine years of worldwide use in 145 other countries. Orlistat experience in more than 25 million patient treatments and more than 100 clinical studies with more than 30,000 patients is unprecedented. One of these studies with Xenical is the four-year landmark XENDOS trial conducted by Roche, its inventor and manufacturer. This study is the longest study ever conducted for a weight-loss medicine.
Xenical (orlistat 120 mg capsules) will remain available by prescription for those who should be treated under the care of a physician. Xenical will continue to be manufactured and sold by Roche.
For more information on alli, go to myalli.com.
About Overweight and Obesity
Currently, approximately 65 percent of U.S. adults are overweight or obese, according to the National Institutes of Health. Research suggests that overweight individuals appear to be on the pathway to obesity.(i, ii) Overweight and obesity are associated with an increased risk of developing health problems such as hypertension, type 2 diabetes and heart disease.(iii) Factors that can contribute to overweight include an abundance of high-calorie foods, low levels of physical activity, behavior, environment, and genetics.(iv) Multiple studies have shown that a modest reduction in weight improves health outcomes significantly in overweight or obese patients.(v, vi)
About GlaxoSmithKline Consumer Healthcare
GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many medicine cabinet staples, including Abreva(R), Aquafresh(R), Sensodyne(R), Tums(R) and Breathe Right(R).
About GlaxoSmithKline
GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: http://www.gsk.com.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report 2004.
(i) Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends
in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
(ii) McTigue KM, Garrett JM, Popkin BM. The natural history of the
development of obesity in a cohort of young US adults between 1981-
1998. Ann Intern Med 2002;136:857-864.
(iii) Centers for Disease Control and Prevention: "Overweight and
Obesity." http://www.cdc.gov/nccdphp/dnpa/obesity/. Accessed
12/22/05.
(iv) Centers for Disease Control and Prevention. "Overweight and Obesity:
Contributing Factors."
http://www.cdc.gov/nccdphp/dnpa/obesity/contributing_factors…
Accessed 12/22/05.
(v) Hauptman J, Lucas C, Baldrin MN, Collins H, Segal K. "Orlistat in
the long-term treatment of obesity in primary care settings."
Archives of Family Medicine 9:160-167.
(vi) NIH, NHLBI. Clinical guidelines on the identification, evaluation,
and treatment of overweight and obesity in adults. HHS, PHS; 1998.
p. 29-41.
SOURCE GlaxoSmithKline Consumer Healthcare
GSK Inquiries, US Media, Brian Jones, +1-215-751-3415, Brian.L.Jones@gsk.com, or
Malesia Dunn, +1-412-200-3544, malesia.a.dunn@gsk.com, or Patricia Seif,
+1-215-751-7709, patricia.r.seif@gsk.com, or US Analyst\Investors, Frank Murdolo,
+1-215-751-7002, or Tom Curry, +1-215-751-5419, or UK Media Inquiries, Philip
Thomson, +020-8047-5502, or Gwenan White, +020-8047-5502, or Alice Hunt,
+020-8047-5502, or European Analyst\Investors Inquiries, Anita Kidgell,
+020-8047-5542, or Sally Ferguson, +020-8047-5543, or David Mawdsley, +020-8047-5564
http://www.prnewswire.com
Copyright (C) 2007 PR Newswire. All rights reserved
Hallo,
wann kamen die News ? Konnten die Amis schon reagieren oder können sie erst heut nachmittag ?
wann kamen die News ? Konnten die Amis schon reagieren oder können sie erst heut nachmittag ?
Antwort auf Beitrag Nr.: 27.504.181 von sbroker84 am 08.02.07 09:45:52News kamen heute Nacht, USA konnte noch nicht reagieren.
Antwort auf Beitrag Nr.: 27.504.236 von axcol am 08.02.07 09:48:27Die Umsätze der letzten Zeit sind aber mehr als dürftig
Antwort auf Beitrag Nr.: 27.504.310 von sportecho am 08.02.07 09:51:53PMED hatte auch null Umsatz bis die News kamen.
Trading Spotlight
Hab nur kurz reingelesen. Wo ist der Bezug zu Dragon Pharma ? Der Haupttext geht doch über GSK
Antwort auf Beitrag Nr.: 27.504.323 von axcol am 08.02.07 09:52:31Werde noch bis 15.30 warten. Bis dahin muß ich mich noch um PDI kümmern
die PR nimmt Bezug auf GlaxoSmithKline!!
Was hat Dragon Pharmaceuticals damit zu tun??????
Was hat Dragon Pharmaceuticals damit zu tun??????
werde mal ein auge drauf werfen,eventuell heute nachmittag in den usa rein 
Antwort auf Beitrag Nr.: 27.504.623 von spekulativ am 08.02.07 10:05:00Die letzte offizielle Meldung welche ich über Dragon finden kann ist vom 14.11.06
Antwort auf Beitrag Nr.: 27.504.323 von axcol am 08.02.07 09:52:31Du bist noch eine Antwort schuldig....
Antwort auf Beitrag Nr.: 27.504.855 von sportecho am 08.02.07 10:13:50News kamen über
http://www.purepennies.com/otcbb_news.shtml
Denke die hängen mit Glaxo irgendwie zusammen.
DRAGON PHARMACEUTICALS
FDA Approves alli(TM) (orlistat 60 mg capsules) Over-The-Counter
2/7/2007
An Innovative and Honest Approach to Weight Loss
Combines a Safe and Effective Product With An Innovative Personalized Support Program
http://www.purepennies.com/otcbb_news.shtml
Denke die hängen mit Glaxo irgendwie zusammen.
DRAGON PHARMACEUTICALS
FDA Approves alli(TM) (orlistat 60 mg capsules) Over-The-Counter
2/7/2007
An Innovative and Honest Approach to Weight Loss
Combines a Safe and Effective Product With An Innovative Personalized Support Program
Antwort auf Beitrag Nr.: 27.504.855 von sportecho am 08.02.07 10:13:50ist doch egal,will hier ja nicht long gehen,heute zum börsenstart usa rein und dann mal sehen,maximal 48std
gruß speku
gruß speku
Habs noch mal in US gesucht. Der zeigt die News an. Bin den Text durchgegangen und kann keinen Bezug herstellen.
Antwort auf Beitrag Nr.: 27.505.640 von sbroker84 am 08.02.07 10:43:37Watch GSK NEWS from 7 Feb!
kann auch, leider, keinen bezug herstellen ..
unter dem u.g. link ( http://www.purepennies.com/otcbb_news.shtml ) ist die meldung unter DRUG einzusehen
unter dem u.g. link ( http://www.purepennies.com/otcbb_news.shtml ) ist die meldung unter DRUG einzusehen
01:00 03Apr07 -Dragon Pharmaceutical Announces 2006 Year End Results <DDD.TO>
CCNMATTHEWS
Dragon Pharmaceutical Inc.
April 2, 2007 - 07:00:01 PM
Dragon Pharmaceutical Announces 2006 Year End Results
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 2, 2007) - Dragon
Pharmaceutical Inc. (TSXDD)(OTCBBRUG)(BBSERP) today announced the
results for its fiscal year ended December 31, 2006. As previously disclosed,
Dragon sold a part of its formulation business effective July 1, 2006,
therefore the financial results of 2005 were reclassified to reflect this
change of business composition.
Financial Highlights for 2006
- Sales increased by 57% to $54.87 million from $35.06 million in 2005, mainly
due to the growth in Chemical Division.
- Gross profit and gross margin increased to $10.02 million and 18.25% from
$4.49 million and 12.80% in 2005.
- The comprehensive income was $5.72 million in 2006 compared to a
comprehensive income of $0.93 million for 2005.
- Comprehensive net income per share increased to $0.07 for 2006 from $0.00
for 2005.
Financial Summary
Sales for 2006 increased 57% to $54.87 million as compared to 2005. The
increase in sales was primarily achieved through the growth of sales from the
Chemical Division, which increased by 68% as compared to 2005.
Gross profit reached $10.02 million, representing an increase of 123% over
2005. The gross margin was increased from 12.80% for 2005 to 18.25%. This is
mainly achieved by lowering the production costs based on technology
renovation and high utilization rate of production facilities.
Total operating expenses were $9.06 million for 2006 and $8.12 million for
2005. The net loss from operation was $0.60 million including two accounting
treatments on non-cash expenses items totaling $1.96 million, out of which
$1.57 million was non-cash accreted interest expenses on long term payables
and $0.39 million was non-cash stock-based compensation expense.
Market Segment
The Company continued to expand the international market outside of China
especially for Chemical products. In 2006, $35.26 million or approximately 64%
of the sales were generated from the sales in the Chinese market, and the
remaining $19.91 million or approximately 36% were from sales in international
markets. In 2005, 70% of the sales were generated from the sales in the
Chinese market, and the remaining 30% were from the sales in international
markets.
Product Segment
Chemical Division was still the strong growth driver for sales in 2006. Of the
total sales, $45.80 million or 83% were from the Chemical Division, $6.61
million or 12% were from the Pharma Division, and $2.46 million or 5% were
from the Biotech Division. For the same period in 2005, 78% of sales were from
the Chemical Division, 11% were from the Pharma Division and 11% were from the
Biotech Division.
"The Company achieved the strong growth in sales under a very challenging
market condition in 2006," said Yanlin Han, Chairman and CEO of the Company.
"The market price for our main product dropped 30% in summer, and, as a
result, only cost-efficient, large scale players, of which we are one, remain
active when the market recovered in later time of the year."
Dragon is the third largest 7ACA producer and the market leader of Clavulanic
Acid in China with a market share of 70%. Despite the unfavorable market
condition, the business still showed a strong cash generating power of 13.67
million over 2006. This helped the Company to lower its debts burden to a more
reasonable level.
"We believe the competition the Company went through in 2006 will help to
restore the market order," said again by Mr. Han. "The Company has proven
itself as a leading player and we are dedicated to doing an even better job."
Notes to Investors
Dragon has launched a new version of website with the same domain address.
www.dragonpharma.com.
This press release contains forward looking statements, including but not
limited to, that the Company will be able to maintain or increase its sales
and market position. These statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
anticipated in the forward looking statement. Readers should not place undue
reliance on forward looking statements, which only reflect the view of
management as of the date hereof. The Company does not undertake the
obligation to publicly revise these forward looking statements to reflect
subsequent events or circumstances. Readers should carefully review the risk
factors and other factors described in its periodic reports filed with the
Securities and Exchange Commission.
FOR FURTHER INFORMATION PLEASE CONTACT:
Dragon Pharmaceutical Inc. Maggie Deng (604) 669-8817 or North America Toll
Free: 1-877-388-3784 Email: irdragon@dragonpharma.com Website:
www.dragonpharma.com
Tuesday, 03 April 2007 01:00:03
CCN [nCCNdbJsra] {C}
ENDS
CCNMATTHEWS
Dragon Pharmaceutical Inc.
April 2, 2007 - 07:00:01 PM
Dragon Pharmaceutical Announces 2006 Year End Results
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 2, 2007) - Dragon
Pharmaceutical Inc. (TSX
DD)(OTCBBRUG)(BBSERP) today announced theresults for its fiscal year ended December 31, 2006. As previously disclosed,
Dragon sold a part of its formulation business effective July 1, 2006,
therefore the financial results of 2005 were reclassified to reflect this
change of business composition.
Financial Highlights for 2006
- Sales increased by 57% to $54.87 million from $35.06 million in 2005, mainly
due to the growth in Chemical Division.
- Gross profit and gross margin increased to $10.02 million and 18.25% from
$4.49 million and 12.80% in 2005.
- The comprehensive income was $5.72 million in 2006 compared to a
comprehensive income of $0.93 million for 2005.
- Comprehensive net income per share increased to $0.07 for 2006 from $0.00
for 2005.
Financial Summary
Sales for 2006 increased 57% to $54.87 million as compared to 2005. The
increase in sales was primarily achieved through the growth of sales from the
Chemical Division, which increased by 68% as compared to 2005.
Gross profit reached $10.02 million, representing an increase of 123% over
2005. The gross margin was increased from 12.80% for 2005 to 18.25%. This is
mainly achieved by lowering the production costs based on technology
renovation and high utilization rate of production facilities.
Total operating expenses were $9.06 million for 2006 and $8.12 million for
2005. The net loss from operation was $0.60 million including two accounting
treatments on non-cash expenses items totaling $1.96 million, out of which
$1.57 million was non-cash accreted interest expenses on long term payables
and $0.39 million was non-cash stock-based compensation expense.
Market Segment
The Company continued to expand the international market outside of China
especially for Chemical products. In 2006, $35.26 million or approximately 64%
of the sales were generated from the sales in the Chinese market, and the
remaining $19.91 million or approximately 36% were from sales in international
markets. In 2005, 70% of the sales were generated from the sales in the
Chinese market, and the remaining 30% were from the sales in international
markets.
Product Segment
Chemical Division was still the strong growth driver for sales in 2006. Of the
total sales, $45.80 million or 83% were from the Chemical Division, $6.61
million or 12% were from the Pharma Division, and $2.46 million or 5% were
from the Biotech Division. For the same period in 2005, 78% of sales were from
the Chemical Division, 11% were from the Pharma Division and 11% were from the
Biotech Division.
"The Company achieved the strong growth in sales under a very challenging
market condition in 2006," said Yanlin Han, Chairman and CEO of the Company.
"The market price for our main product dropped 30% in summer, and, as a
result, only cost-efficient, large scale players, of which we are one, remain
active when the market recovered in later time of the year."
Dragon is the third largest 7ACA producer and the market leader of Clavulanic
Acid in China with a market share of 70%. Despite the unfavorable market
condition, the business still showed a strong cash generating power of 13.67
million over 2006. This helped the Company to lower its debts burden to a more
reasonable level.
"We believe the competition the Company went through in 2006 will help to
restore the market order," said again by Mr. Han. "The Company has proven
itself as a leading player and we are dedicated to doing an even better job."
Notes to Investors
Dragon has launched a new version of website with the same domain address.
www.dragonpharma.com.
This press release contains forward looking statements, including but not
limited to, that the Company will be able to maintain or increase its sales
and market position. These statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
anticipated in the forward looking statement. Readers should not place undue
reliance on forward looking statements, which only reflect the view of
management as of the date hereof. The Company does not undertake the
obligation to publicly revise these forward looking statements to reflect
subsequent events or circumstances. Readers should carefully review the risk
factors and other factors described in its periodic reports filed with the
Securities and Exchange Commission.
FOR FURTHER INFORMATION PLEASE CONTACT:
Dragon Pharmaceutical Inc. Maggie Deng (604) 669-8817 or North America Toll
Free: 1-877-388-3784 Email: irdragon@dragonpharma.com Website:
www.dragonpharma.com
Tuesday, 03 April 2007 01:00:03
CCN [nCCNdbJsra] {C}
ENDS
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 90 | ||
| 86 | ||
| 86 | ||
| 60 | ||
| 55 | ||
| 53 | ||
| 47 | ||
| 41 | ||
| 33 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 32 | ||
| 29 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 26 | ||
| 24 | ||
| 24 | ||
| 22 |
